Autism Speaks to Host Symposium on the Development of Novel Neuropharmacological Therapeutics for Autism
Satellite Symposium Will be Held at the 46th Annual Meeting of the American College of Neuropsychopharmacology on December 14, 2007 in Boca Raton, Fla.
NEW YORK, NY (December 3, 2007) – Autism Speaks, the largest non-profit organization dedicated to increasing awareness of autism and raising money to fund autism research, today announced that it will host a research symposium on the Development of Novel Neuropharmacological Therapeutics for Autism on December 14, 2007, as a satellite symposium of the 46th annual meeting of the American College of Neuropsychopharmacology (ACNP) in Boca Raton, Fla. The symposium is associated with the main ACNP annual meeting (December 9-13).
The symposium will convene about 100 world-renowned scientists, clinicians and practitioners. It, will focus on advances in basic, clinical and industry-based research and will present an integrated view of the approaches in use to discover and develop novel medications for autism treatment. The program will illustrate recent advances in the field, examine the broad scope of current, exploitable opportunities for drug development, and provide an open forum for discussing barriers to further progress in defining this condition and identifying new therapeutics.
Notable presenters include Mark Bear, Ph.D. of Massachusetts Institute of Technology, Jacqueline Crawley, Ph.D. of the National Institute of Mental Health, Eric Hollander, M.D. of Mount Sinai School of Medicine, Lawrence Scahill, Ph.D. of Yale University, Gwen Zornberg, M.D., Sc.D. of the Food and Drug Administration and other researchers from academia, clinical practice and the pharmaceutical industry.
Presentation topics will include clinical trial design and the best ways to test new drug candidates; the complexity of the disorder and the challenges in selecting study participants as well as new technologies that may facilitate this process; novel drug targets; and the role of industry in developing new medicines for these targets.
About Autism Speaks
Autism Speaks is dedicated to increasing awareness of autism spectrum disorders, to funding research into the causes, prevention, treatments and cure for autism, and to advocating for the needs of affected families. It was founded in February 2005 by Suzanne and Bob Wright, the grandparents of a child with autism. Bob Wright is Vice Chairman, General Electric, and served as chief executive officer of NBC for more than twenty years. Autism Speaks has merged with both the National Alliance for Autism Research (NAAR) and Cure Autism Now (CAN), bringing together the nation’s three leading autism advocacy organizations. To learn more about Autism Speaks, please visit http://www.autismspeaks.org.
About the ACNP
The principal function of the American College of Neuropsychopharmacology (ACNP) is to further research and education in neuropsychopharmacology and related fields by specifically: Promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of diseases of the nervous system including psychiatric, neurological, behavioral and addictive disorders; Encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances in these disorders.
Autistic people have fought the inclusion of ABA in therapy for us since before Autism Speaks, and other non-Autistic-led autism organizations, started lobbying legislation to get it covered by insurances and Medicaid.
ABA is a myth originally sold to parents that it would keep their Autistic child out of an institution. Today, parents are told that with early intervention therapy their child will either be less Autistic or no longer Autistic by elementary school, and can be mainstreamed in typical education classes. ABA is very expensive to pay out of pocket. Essentially, Autism Speaks has justified the big price tag up front will offset the overall burden on resources for an Autistic’s lifetime. The recommendation for this therapy is 40 hours a week for children and toddlers.
The original study that showed the success rate of ABA to be at 50% has never been replicated. In fact, the study of ABA by United States Department of Defense was denounced as a failure. Not just once, but multiple times. Simply stated: ABA doesn’t work. In study after repeated study: ABA (conversion therapy) doesn’t work.
What more recent studies do show: Autistics who experienced ABA therapy are at high risk to develop PTSD and other lifelong trauma-related conditions. Historically, the autism organizations promoting ABA as a cure or solution have silenced Autistic advocates’ opposition. ABA is also known as gay conversion therapy.
The ‘cure’ for Autistics not born yet is the prevention of birth.
The ‘cure’ is a choice to terminate a pregnancy based on ‘autism risk.’ The cure is abortion. This is the same ‘cure’ society has for Down Syndrome.
This is eugenics 2021. Instead of killing Autistics and disabled children in gas chambers or ‘mercy killings’ like in Aktion T4, it’ll happen at the doctor’s office, quietly, one Autistic baby at a time. Different approaches yes, but still eugenics and the extinction of an entire minority group of people.
Fact: You can’t cure Autistics from being Autistic.
Fact: You can’t recover an Autistic from being Autistic.
Fact: You can groom an Autistic to mask and hide their traits. Somewhat. … however, this comes at the expense of the Autistic child, promotes Autistic Burnout (this should not be confused with typical burnout, Autistic Burnout can kill Autistics), and places the Autistic child at high risk for PTSD and other lifelong trauma-related conditions.